2023-01-012023-12-312023-12-31falseNI664179Univ8 Genomics Ltd2024-08-0572110iso4217:GBPxbrli:pureNI6641792023-01-01NI6641792023-12-31NI6641792023-01-012023-12-31NI6641792022-01-01NI6641792022-12-31NI6641792022-01-012022-12-31NI664179bus:SmallEntities2023-01-012023-12-31NI664179bus:AuditExempt-NoAccountantsReport2023-01-012023-12-31NI664179bus:FullAccounts2023-01-012023-12-31NI664179bus:PrivateLimitedCompanyLtd2023-01-012023-12-31NI664179core:WithinOneYear2023-12-31NI664179core:AfterOneYear2023-12-31NI664179core:WithinOneYear2022-12-31NI664179core:AfterOneYear2022-12-31NI664179core:ShareCapital2023-12-31NI664179core:SharePremium2023-12-31NI664179core:RevaluationReserve2023-12-31NI664179core:OtherReservesSubtotal2023-12-31NI664179core:RetainedEarningsAccumulatedLosses2023-12-31NI664179core:ShareCapital2022-12-31NI664179core:SharePremium2022-12-31NI664179core:RevaluationReserve2022-12-31NI664179core:OtherReservesSubtotal2022-12-31NI664179core:RetainedEarningsAccumulatedLosses2022-12-31NI664179core:LandBuildings2023-12-31NI664179core:PlantMachinery2023-12-31NI664179core:Vehicles2023-12-31NI664179core:FurnitureFittings2023-12-31NI664179core:OfficeEquipment2023-12-31NI664179core:NetGoodwill2023-12-31NI664179core:IntangibleAssetsOtherThanGoodwill2023-12-31NI664179core:ListedExchangeTraded2023-12-31NI664179core:UnlistedNon-exchangeTraded2023-12-31NI664179core:LandBuildings2022-12-31NI664179core:PlantMachinery2022-12-31NI664179core:Vehicles2022-12-31NI664179core:FurnitureFittings2022-12-31NI664179core:OfficeEquipment2022-12-31NI664179core:NetGoodwill2022-12-31NI664179core:IntangibleAssetsOtherThanGoodwill2022-12-31NI664179core:ListedExchangeTraded2022-12-31NI664179core:UnlistedNon-exchangeTraded2022-12-31NI664179core:LandBuildings2023-01-012023-12-31NI664179core:PlantMachinery2023-01-012023-12-31NI664179core:Vehicles2023-01-012023-12-31NI664179core:FurnitureFittings2023-01-012023-12-31NI664179core:OfficeEquipment2023-01-012023-12-31NI664179core:NetGoodwill2023-01-012023-12-31NI664179core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-31NI664179core:ListedExchangeTraded2023-01-012023-12-31NI664179core:UnlistedNon-exchangeTraded2023-01-012023-12-31NI664179core:MoreThanFiveYears2023-01-012023-12-31NI664179core:Non-currentFinancialInstruments2023-12-31NI664179core:Non-currentFinancialInstruments2022-12-31NI664179dpl:CostSales2023-01-012023-12-31NI664179dpl:DistributionCosts2023-01-012023-12-31NI664179core:LandBuildings2023-01-012023-12-31NI664179core:PlantMachinery2023-01-012023-12-31NI664179core:Vehicles2023-01-012023-12-31NI664179core:FurnitureFittings2023-01-012023-12-31NI664179core:OfficeEquipment2023-01-012023-12-31NI664179dpl:AdministrativeExpenses2023-01-012023-12-31NI664179core:NetGoodwill2023-01-012023-12-31NI664179core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-31NI664179dpl:GroupUndertakings2023-01-012023-12-31NI664179dpl:ParticipatingInterests2023-01-012023-12-31NI664179dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-31NI664179core:ListedExchangeTraded2023-01-012023-12-31NI664179dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-31NI664179core:UnlistedNon-exchangeTraded2023-01-012023-12-31NI664179dpl:CostSales2022-01-012022-12-31NI664179dpl:DistributionCosts2022-01-012022-12-31NI664179core:LandBuildings2022-01-012022-12-31NI664179core:PlantMachinery2022-01-012022-12-31NI664179core:Vehicles2022-01-012022-12-31NI664179core:FurnitureFittings2022-01-012022-12-31NI664179core:OfficeEquipment2022-01-012022-12-31NI664179dpl:AdministrativeExpenses2022-01-012022-12-31NI664179core:NetGoodwill2022-01-012022-12-31NI664179core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-31NI664179dpl:GroupUndertakings2022-01-012022-12-31NI664179dpl:ParticipatingInterests2022-01-012022-12-31NI664179dpl:GroupUndertakingscore:ListedExchangeTraded2022-01-012022-12-31NI664179core:ListedExchangeTraded2022-01-012022-12-31NI664179dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-01-012022-12-31NI664179core:UnlistedNon-exchangeTraded2022-01-012022-12-31NI664179core:NetGoodwill2023-12-31NI664179core:IntangibleAssetsOtherThanGoodwill2023-12-31NI664179core:LandBuildings2023-12-31NI664179core:PlantMachinery2023-12-31NI664179core:Vehicles2023-12-31NI664179core:FurnitureFittings2023-12-31NI664179core:OfficeEquipment2023-12-31NI664179core:AfterOneYear2023-12-31NI664179core:WithinOneYear2023-12-31NI664179core:ListedExchangeTraded2023-12-31NI664179core:UnlistedNon-exchangeTraded2023-12-31NI664179core:ShareCapital2023-12-31NI664179core:SharePremium2023-12-31NI664179core:RevaluationReserve2023-12-31NI664179core:OtherReservesSubtotal2023-12-31NI664179core:RetainedEarningsAccumulatedLosses2023-12-31NI664179core:NetGoodwill2022-12-31NI664179core:IntangibleAssetsOtherThanGoodwill2022-12-31NI664179core:LandBuildings2022-12-31NI664179core:PlantMachinery2022-12-31NI664179core:Vehicles2022-12-31NI664179core:FurnitureFittings2022-12-31NI664179core:OfficeEquipment2022-12-31NI664179core:AfterOneYear2022-12-31NI664179core:WithinOneYear2022-12-31NI664179core:ListedExchangeTraded2022-12-31NI664179core:UnlistedNon-exchangeTraded2022-12-31NI664179core:ShareCapital2022-12-31NI664179core:SharePremium2022-12-31NI664179core:RevaluationReserve2022-12-31NI664179core:OtherReservesSubtotal2022-12-31NI664179core:RetainedEarningsAccumulatedLosses2022-12-31NI664179core:NetGoodwill2022-01-01NI664179core:IntangibleAssetsOtherThanGoodwill2022-01-01NI664179core:LandBuildings2022-01-01NI664179core:PlantMachinery2022-01-01NI664179core:Vehicles2022-01-01NI664179core:FurnitureFittings2022-01-01NI664179core:OfficeEquipment2022-01-01NI664179core:AfterOneYear2022-01-01NI664179core:WithinOneYear2022-01-01NI664179core:ListedExchangeTraded2022-01-01NI664179core:UnlistedNon-exchangeTraded2022-01-01NI664179core:ShareCapital2022-01-01NI664179core:SharePremium2022-01-01NI664179core:RevaluationReserve2022-01-01NI664179core:OtherReservesSubtotal2022-01-01NI664179core:RetainedEarningsAccumulatedLosses2022-01-01NI664179core:AfterOneYear2023-01-012023-12-31NI664179core:WithinOneYear2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:CostValuation2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-31NI664179core:Non-currentFinancialInstrumentscore:CostValuation2023-12-31NI664179core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-31NI664179core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-31NI664179core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-31NI664179core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-31NI664179core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-31NI664179core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-31NI664179core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-31NI664179core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-31NI664179core:Non-currentFinancialInstrumentscore:CostValuation2022-12-31NI664179core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-12-31NI664179core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-12-31NI664179core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-12-31NI664179core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-12-31NI664179core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-12-31NI664179core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-12-31NI664179core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-12-31NI664179core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-12-31NI664179bus:Director12023-01-012023-12-31NI664179bus:Director22023-01-012023-12-31NI664179bus:Director32023-01-012023-12-31NI664179bus:Director42023-01-012023-12-31NI664179bus:Director52023-01-012023-12-31

Univ8 Genomics Ltd

Registered Number
NI664179
(Northern Ireland)

Unaudited Financial Statements for the Year ended
31 December 2023

Univ8 Genomics Ltd
Company Information
for the year from 1 January 2023 to 31 December 2023

Directors

Gonzalez De Castro, David, Prof
Moore, William David John
Peach, James Hugh Fennell
Ribate, Ignacio
Ribeiro, David

Registered Address

63 University Road
Belfast
BT7 1NF

Registered Number

NI664179 (Northern Ireland)
Univ8 Genomics Ltd
Balance Sheet as at
31 December 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Intangible assets316,6458,365
16,6458,365
Current assets
Stocks415,43512,074
Debtors55,6513,468
Cash at bank and on hand155,98092,748
177,066108,290
Creditors amounts falling due within one year6(35,180)(13,270)
Net current assets (liabilities)141,88695,020
Total assets less current liabilities158,531103,385
Net assets158,531103,385
Capital and reserves
Called up share capital22
Share premium131,347113,395
Profit and loss account27,182(10,012)
Shareholders' funds158,531103,385
The financial statements were approved and authorised for issue by the Board of Directors on 5 August 2024, and are signed on its behalf by:
Gonzalez De Castro, David, Prof
Director
Registered Company No. NI664179
Univ8 Genomics Ltd
Notes to the Financial Statements
for the year ended 31 December 2023

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Northern Ireland. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account. Amortisation is charged at both 10% and 20% straight line depending on the nature of the intangible.
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
Government grants or assistance
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received. A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.
2.Average number of employees

20232022
Average number of employees during the year10
3.Intangible assets

Other

Total

££
Cost or valuation
At 01 January 2310,12410,124
Additions10,54410,544
At 31 December 2320,66820,668
Amortisation and impairment
At 01 January 231,7591,759
Charge for year2,2642,264
At 31 December 234,0234,023
Net book value
At 31 December 2316,64516,645
At 31 December 228,3658,365
4.Stocks

2023

2022

££
Other stocks15,43512,074
Total15,43512,074
5.Debtors: amounts due within one year

2023

2022

££
Trade debtors / trade receivables5,6512,860
Other debtors-608
Total5,6513,468
6.Creditors: amounts due within one year

2023

2022

££
Taxation and social security15,1946,632
Accrued liabilities and deferred income19,9866,638
Total35,18013,270